Premium
Review article: how and when to use ciclosporin in ulcerative colitis
Author(s) -
DURAI D.,
HAWTHORNE A. B.
Publication year - 2005
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2005.02680.x
Subject(s) - ciclosporin , medicine , ulcerative colitis , colectomy , prednisolone , colitis , surgery , gastroenterology , anesthesia , chemotherapy , disease
Summary Although colectomy for ulcerative colitis is curative, long‐term quality of life is reduced. Intravenous ciclosporin 4 mg/kg/day has significant toxicity. There is now evidence that low‐dose ciclosporin (2 mg/kg daily by intravenous infusion, or 5–6 mg/kg daily in a twice daily oral dosage) has an acceptable safety profile, even when used in combination with corticosteroids. Drug dosage should be adjusted to the levels of 150–250 ng/mL initially (random levels during intravenous infusion, or trough levels for oral use). Ciclosporin should be considered not only in those who have failed 7 days of corticosteroids, but also in fulminant colitis at day 3, if not responding to corticosteroids. The drug should be avoided in frail or elderly patients with significant comorbidity, and also where colectomy is likely to be necessary in the short to medium term. Ciclosporin should not be continued for more than 7 days, unless there is a definite response. A 70–80% initial response is likely, and responders are discharged on oral ciclosporin, adding thiopurines and tailing prednisolone rapidly. The drug should be continued for 3 months. The likelihood of avoiding colectomy over 2–3 years is 40–50%. More studies are needed to evaluate the use of oral ciclosporin in corticosteroid‐refractory colitis in out‐patients, and to assess whether monotherapy (without corticosteroids) is significantly safer, without loss of efficacy.